Stanley C. Jordan, MD
Director, HLA and Transplant Immunology Laboratory, Comprehensive Transplant Center
Director, Division of Nephrology
Director, Nephrology
Medical Director, Kidney Transplant Program, Comprehensive Transplant Center
Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory
Medical Director, Kidney Transplant Program
Professor, Medicine
Clinical Office
Comprehensive Transplant Center
8900 Beverly Blvd
Los Angeles, CA
90048
Phone:
310-423-2641
Fax:
310-423-0234
Stanley C. Jordan, MD
Director, HLA and Transplant Immunology Laboratory, Comprehensive Transplant Center
Director, Division of Nephrology
Director, Nephrology
Medical Director, Kidney Transplant Program, Comprehensive Transplant Center
Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory
Medical Director, Kidney Transplant Program
Professor, Medicine
Specialty
- IM/Nephrology
- Peds - Nephrology
Subspecialty
- Transplant Nephrology
Education
- Medical School: University of North Carolina, 1973
- Internship: UCLA, 1974
- Residency: UCLA, 1976
Cedars-Sinai Affiliations
Awards & Activities
- Outstanding Clinical Investigator Award, Western Society for Clinical Investigation, 2016
- Prize for Research In Scientific Medicine (PRISM), 2015
- Pioneer in Medicine Award, 2015
- National Kidney Foundation Gift of Life Award, 2006
- UCLA Alumni Association Medical Science Award, 2006
Publications
- Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC: Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatric transplantation, , 2008
- Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med., 359(3): 242-51, 2008
- Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC: Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am. J. Transplant., 8(1): 144-9, 2007
Languages Spoken
English
Make an Appointment